King Wealth Management Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

King Wealth Management Group’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,000	Closed	-$341K	–	149
2022 Q3	$341K	Hold	8,000	–	–	0.09%	102
2022 Q2	$446K	Buy	8,000 +2,000	+33%	+$119K	0.11%	88
2022 Q1	$372K	Hold	6,000	–	–	0.07%	114
2021 Q4	$331K	Hold	6,000	–	–	0.06%	132
2021 Q3	$316K	Hold	6,000	–	–	0.06%	134
2021 Q2	$413K	Hold	6,000	–	–	0.08%	111
2021 Q1	$463K	Buy	+6,000	New	+$553K	0.1%	100

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

King Wealth Management Group's LKFT Position: Q4 2022 in Review

King Wealth Management Group sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 8,000 shares — an estimated $341K sold.

King Wealth Management Group first reported a position in LKFT in Q1 2021 and held it in 7 quarters. The position peaked at $463K in Q1 2021. 75 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

King Wealth Management Group reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
King Wealth Management Group sold 8,000 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $341K.
King Wealth Management Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 7 quarters.
King Wealth Management Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $463K in Q1 2021.
75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on King Wealth Management Group's 13F filing for Q4 2022, filed 9 Feb 2023.